Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 44

1.

Protocol: changes in rates of opioid overdose and poisoning events in an integrated health system following the introduction of a formulation of OxyContin® with abuse-deterrent properties.

Janoff SL, Perrin NA, Coplan PM, Chilcoat HD, Campbell CI, Green CA.

BMC Pharmacol Toxicol. 2016 May 14;17(1):21. doi: 10.1186/s40360-016-0064-y.

2.

Demographic, Insurance, and Health Characteristics of Newly Enrolled HIV-Positive Patients After Implementation of the Affordable Care Act in California.

Satre DD, Parthasarathy S, Altschuler A, Silverberg MJ, Storholm E, Campbell CI.

Am J Public Health. 2016 Jul;106(7):1211-3. doi: 10.2105/AJPH.2016.303126. Epub 2016 Apr 14.

PMID:
27077361
3.

High-Deductible Health Plans: Implications for Substance Use Treatment.

Parthasarathy S, Campbell CI.

Health Serv Res. 2016 Feb 3. doi: 10.1111/1475-6773.12456. [Epub ahead of print]

PMID:
26840191
4.

Physician versus non-physician delivery of alcohol screening, brief intervention and referral to treatment in adult primary care: the ADVISe cluster randomized controlled implementation trial.

Mertens JR, Chi FW, Weisner CM, Satre DD, Ross TB, Allen S, Pating D, Campbell CI, Lu YW, Sterling SA.

Addict Sci Clin Pract. 2015 Nov 19;10:26. doi: 10.1186/s13722-015-0047-0.

5.

IGF-IR mediated mammary tumorigenesis is enhanced during pubertal development.

Jones RA, Watson KL, Campbell CI, Moorehead RA.

PLoS One. 2014 Sep 26;9(9):e108781. doi: 10.1371/journal.pone.0108781. eCollection 2014.

6.

Do patient-perceived pros and cons of opioids predict sustained higher-dose use?

Thielke SM, Turner JA, Shortreed SM, Saunders K, Leresche L, Campbell CI, Weisner CC, Korff MV.

Clin J Pain. 2014 Feb;30(2):93-101. doi: 10.1097/AJP.0b013e31828e361b.

7.

12-step participation and outcomes over 7 years among adolescent substance use patients with and without psychiatric comorbidity.

Chi FW, Sterling S, Campbell CI, Weisner C.

Subst Abus. 2013;34(1):33-42. doi: 10.1080/08897077.2012.691780.

8.

Prescribed opioid difficulties, depression and opioid dose among chronic opioid therapy patients.

Merrill JO, Von Korff M, Banta-Green CJ, Sullivan MD, Saunders KW, Campbell CI, Weisner C.

Gen Hosp Psychiatry. 2012 Nov-Dec;34(6):581-7. doi: 10.1016/j.genhosppsych.2012.06.018. Epub 2012 Sep 5.

9.

Depression and prescription opioid misuse among chronic opioid therapy recipients with no history of substance abuse.

Grattan A, Sullivan MD, Saunders KW, Campbell CI, Von Korff MR.

Ann Fam Med. 2012 Jul-Aug;10(4):304-11. doi: 10.1370/afm.1371.

10.

Depression and ambivalence toward chronic opioid therapy for chronic noncancer pain.

Howe CQ, Sullivan MD, Saunders KW, Merrill JO, Banta-Green CJ, Weisner C, Campbell CI, Von Korff M.

Clin J Pain. 2012 Sep;28(7):561-6. doi: 10.1097/AJP.0b013e31823ade59.

11.

12-Step participation reduces medical use costs among adolescents with a history of alcohol and other drug treatment.

Mundt MP, Parthasarathy S, Chi FW, Sterling S, Campbell CI.

Drug Alcohol Depend. 2012 Nov 1;126(1-2):124-30. doi: 10.1016/j.drugalcdep.2012.05.002. Epub 2012 May 26.

12.

Concurrent use of alcohol and sedatives among persons prescribed chronic opioid therapy: prevalence and risk factors.

Saunders KW, Von Korff M, Campbell CI, Banta-Green CJ, Sullivan MD, Merrill JO, Weisner C.

J Pain. 2012 Mar;13(3):266-75. doi: 10.1016/j.jpain.2011.11.004. Epub 2012 Jan 29.

13.

Twelve-Step attendance trajectories over 7 years among adolescents entering substance use treatment in an integrated health plan.

Chi FW, Campbell CI, Sterling S, Weisner C.

Addiction. 2012 May;107(5):933-42. doi: 10.1111/j.1360-0443.2011.03758.x. Epub 2012 Feb 11.

14.
15.

Transgenic IGF-IR overexpression induces mammary tumors with basal-like characteristics, whereas IGF-IR-independent mammary tumors express a claudin-low gene signature.

Franks SE, Campbell CI, Barnett EF, Siwicky MD, Livingstone J, Cory S, Moorehead RA.

Oncogene. 2012 Jul 5;31(27):3298-309. doi: 10.1038/onc.2011.486. Epub 2011 Oct 24.

16.

Murine mammary tumor cells with a claudin-low genotype.

Campbell CI, Thompson DE, Siwicky MD, Moorehead RA.

Cancer Cell Int. 2011 Aug 16;11:28. doi: 10.1186/1475-2867-11-28.

17.

Prescription long-term opioid use in HIV-infected patients.

Silverberg MJ, Ray GT, Saunders K, Rutter CM, Campbell CI, Merrill JO, Sullivan MD, Banta-Green CJ, Von Korff M, Weisner C.

Clin J Pain. 2012 Jan;28(1):39-46. doi: 10.1097/AJP.0b013e3182201a0f.

18.

Time-scheduled vs. pain-contingent opioid dosing in chronic opioid therapy.

Von Korff M, Merrill JO, Rutter CM, Sullivan M, Campbell CI, Weisner C.

Pain. 2011 Jun;152(6):1256-62. doi: 10.1016/j.pain.2011.01.005. Epub 2011 Feb 5.

19.
20.

Age and gender trends in long-term opioid analgesic use for noncancer pain.

Campbell CI, Weisner C, Leresche L, Ray GT, Saunders K, Sullivan MD, Banta-Green CJ, Merrill JO, Silverberg MJ, Boudreau D, Satre DD, Von Korff M.

Am J Public Health. 2010 Dec;100(12):2541-7. doi: 10.2105/AJPH.2009.180646. Epub 2010 Aug 19.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk